A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.
Chemotherapy-Induced Thrombocytopenia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Cancer|Oncology|Thrombocytopenia
BIOLOGICAL: AMG 531
Change in Platelet Nadir, Change in platelet nadir from the previous qualifying cycle to the first treatment cycle., 32 weeks
Percentage of Subjects Experiencing Grade 3 or 4 Thrombocytopenia, Percentage of subjects experiencing grade 3 and/or 4 thrombocytopenia (\<50 x 10\^9/L, and \<25 x 10\^9/L), 32 weeks|Duration of Grade 3 or 4 Thrombocytopenia, Duration of grade 3 and/or 4 thrombocytopenia (\<50 x 10\^9/L and \<25 x 10\^9/L, respectively), 32 weeks|Percentage of Subjects That Received Platelet Transfusions, Percentage of subjects that received platelet transfusions during the first romiplostim treatment cycle, 32 weeks
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.